GEMOX
Checked 2026-09-09
Advanced biliary tract cancer when cisplatin is unsuitable; also used in pancreatic cancer and some lymphomas
Also called GEMCITABINE-OXALIPLATIN, gemcitabine-oxaliplatin.
One cycle
every 14 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Gemcitabine Nucleoside analogue (deoxycytidine) | 1,000 mg/m² | IV | D1 | |
Oxaliplatin Third-generation platinum (DACH-platinum) | 100 mg/m² | IV | D2 |
Cycles
until progression or 6 months
14-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- Gemcitabine plus cisplatin (with durvalumab or pembrolizumab) is the reference first-line regimen in biliary cancer; GEMOX is the cisplatin-free alternative.
- Cumulative oxaliplatin neuropathy limits duration.
Used in
Products
Source
André, Annals of Oncology 2004: GEMOX in advanced biliary tract adenocarcinoma
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
mFOLFOX6
Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line
every 14 days × 12
FOLFIRINOX
Metastatic pancreatic cancer, performance status 0-1
every 14 days × 12
mFOLFIRINOX (adjuvant)
Resected pancreatic cancer, fit patients, started within 12 weeks of surgery
every 14 days × 12
Gemcitabine + nab-paclitaxel
Metastatic pancreatic cancer first line; adjuvant option when FOLFIRINOX is not tolerated
every 28 days
Gemcitabine monotherapy
Frail patients or adjuvant when combinations are not tolerated
every 28 days × 6
NALIRIFOX
Metastatic pancreatic cancer first line
every 14 days
Gemcitabine + cisplatin
Advanced biliary tract cancer first line (with durvalumab or pembrolizumab); cisplatin-eligible urothelial cancer
every 21 days × 8
Olaparib maintenance
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
every 28 days × 2